Inhibition of Thrombin-Activatable Fibrinolysis Inhibitor and Plasminogen Activator Inhibitor-1 Reduces Ischemic Brain Damage in Mice | Zendy

Frederik Denorme | Zendy; Tine Wyseure | Zendy; Miet Peeters | Zendy; Nele Vandeputte | Zendy; Ann Gils | Zendy; Hans Deckmyn | Zendy; Karen Vanhoorelbeke | Zendy; Paul Declerck | Zendy; Simon F. De Meyer | Zendy

Open Access

Inhibition of Thrombin-Activatable Fibrinolysis Inhibitor and Plasminogen Activator Inhibitor-1 Reduces Ischemic Brain Damage in Mice

Author(s) -

Frederik Denorme,

Tine Wyseure,

Miet Peeters,

Nele Vandeputte,

Ann Gils,

Hans Deckmyn,

Karen Vanhoorelbeke,

Paul Declerck,

Simon F. De Meyer

Publication year - 2016

Publication title -

stroke

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.397

H-Index - 319

eISSN - 1524-4628

pISSN - 0039-2499

DOI - 10.1161/strokeaha.116.014091

Subject(s) - medicine , fibrinolysis , fibrin , stroke (engine) , plasminogen activator , tissue plasminogen activator , ischemia , plasminogen activator inhibitor 1 , thrombin , cerebral infarction , middle cerebral artery , pharmacology , brain ischemia , anesthesia , cardiology , immunology , platelet , mechanical engineering , engineering

Cerebral ischemia and reperfusion is associated with activation of the coagulation cascade and fibrin deposition in cerebral microvessels. Both thrombin-activatable fibrinolysis inhibitor (TAFI) and plasminogen activator inhibitor-1 (PAI-1) attenuate fibrinolysis and are therefore attractive targets for the treatment of ischemic stroke.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research